ICPT : Analysis & Opinions

  1. Intercept Liver Drug Gets Conditional EU OK (ICPT)

    October 14, 2016
    Intercept Pharmaceuticals' Ocaliva liver disease drug moves one step closer to final European approval.
  2. The Top 5 Mid-Cap Biotechnology Stocks for 2016 (ALNY, ICPT)

    January 5, 2016
    Discover the top five mid-cap biotechnology stocks for 2016, with a brief summary, growth outlook and expected price target ...
  3. Every Biotech Catalyst Wedbush Is Watching In 2016

    January 2, 2016
    In a new report, Wedbush analyst Liana Moussatos breaks down potential 2016 catalysts for every emerging pharmaceuticals ...
  4. 4 Reasons Intercept Pharmaceuticals Should Be on Your Radar (ICPT)

    August 20, 2015
    Learn about Intercept Pharmaceuticals and what type of biopharmaceuticals it seeks to create. Understand four reasons why ...
  5. Intercept Pharmaceuticals Makes a Breakthrough

    July 7, 2015
    On June 30, 2015 Intercept Pharmaceuticals Inc announced two important regulatory milestones for its pipeline drug, obeticholic ...
  6. Will This Drug Beat Gilead to Market in NASH? (GILD, ICPT)

    May 22, 2015
    A race of sorts is on between Gilead Sciences (NASDAQ: GILD) and Intercept Pharmaceuticals (NASDAQ: ICPT). In a bid to be ...
  7. Meet The 5 Companies Loving Obamacare

    November 4, 2014
Trading Center